Alterations in mitochondrial respiration and reactive oxygen species in patients poisoned with carbon monoxide treated with hyperbaric oxygen

David H. Jang1*, Utsha G. Khatri1, Brenna P. Shortal2, Matthew Kelly1,4, Kevin Hardy1,4, David S. Lambert1,4 and David M. Eckmann2,3,6,7

Abstract

Background: Carbon monoxide (CO) poisoning is the leading cause of poisoning mortality and morbidity in the USA. Carboxyhemoglobin (COHb) levels are not predictive of severity or prognosis. At this time, the measurement of mitochondrial respiration may serve as a biomarker in CO poisoning. The primary objective of this study was to assess changes in mitochondrial function consisting of respiration and generation of reactive oxygen species (ROS) in peripheral blood mononuclear cells (PBMCs) obtained from patients with CO poisoning.

Methods: PBMCs from patients having confirmed CO exposure treated with hyperbaric oxygen or HBO (CO group) and healthy controls (control group) were analyzed with high-resolution respirometry. PBMCs were placed in a 2-ml chamber at a final concentration of 3–4×10^6 cells/ml to simultaneously obtain both respiration and hydrogen peroxide (H_2O_2) production. In the CO group, we performed measurements before and after patients underwent their first HBO treatment.

Results: We enrolled a total of 17 subjects, including 7 subjects with confirmed CO poisoning and 10 subjects in the control group. The CO group included five (71.4%) men and two (28.6%) women having a median COHb of 28%. There was a significant decrease in respiration as measured in pmol O_2 × s^{-1} × 10^{-6} PBMCs in the CO group (pre-HBO) when compared to the control group: maximal respiration (18.4 ± 2.4 versus 35.4 ± 2.8, P < 0.001); uncoupled Complex I respiration (19.8 ± 1.8 versus 41.1 ± 3.8, P < 0.001); uncoupled Complex I + II respiration (32.3 ± 3.2 versus 58.3 ± 3.1, P < 0.001); Complex IV respiration (43.5 ± 2.9 versus 63.6 ± 6.3, P < 0.05). There were also similar differences measured in the CO group before and after HBO treatment with an overall increase in respiration present after treatment. We also determined the rate of H_2O_2 production simultaneously with the measurement of respiration. There was an overall significant increase in the H_2O_2 production in the CO group after HBO treatment when compared to prior HBO treatment and the control group.

(Continued on next page)
Conclusions: In this study, PBMCs obtained from subjects with CO poisoning have an overall decrease in respiration (similar H$_2$O$_2$ production) when compared to controls. The inhibition of Complex IV respiration is from CO binding leading to a downstream decrease in respiration at other complexes. PBMCs obtained from CO-poisoned individuals immediately following initial HBO therapy displayed an overall increase in both respiration and H$_2$O$_2$ production. The study findings demonstrate that treatment with HBO resulted in improved cellular respiration but a higher H$_2$O$_2$ production. It is unclear if the increased production of H$_2$O$_2$ in HBO treatment is detrimental.

Keywords: Mitochondria, Carbon monoxide, Reactive oxygen species, Hyperbaric oxygen

Background
Carbon monoxide (CO) is a colorless and odorless gas that is an important cause of poisoning mortality and morbidity in the USA with approximately 15,000 intentional cases annually accounting for over two thirds of reported death. Specifically, death from CO poisoning has been reported to be between 1000 to 2000 in some years with over 50,000 CO cases seen in emergency departments in the USA annually, with approximately 10–15% requiring hospitalization [1, 2]. It is estimated that CO poisoning results in over $1 billion annually related to hospital costs and lost earnings. The most serious complication for survivors of consequential CO exposure is delayed neurological or neurocognitive sequela which occurs in up to 50% of patients having symptomatic CO poisoning [3, 4].

The mechanism for CO poisoning includes lipid peroxidation, decreased oxygen carrying capacity, and inhibition of cytochrome c oxidase or Complex IV (CIV) [5–8]. The standard treatment for CO poisoning recommended by the Undersea & Hyperbaric Medical Society is hyperbaric oxygen (HBO) therapy to decrease half-life but also to prevent lipid peroxidation. There is one clinical trial which was the only RCT to meet CONSORT criteria that did find efficacy of HBO [9]. Despite recommendations, the effectiveness of HBO is widely debated with a Cochrane review concluding that existing randomized trials do not establish that administration of HBO to patients with CO poisoning reduces the incidence of adverse neurologic outcomes [10]. There is a clear need for a better understanding of the interaction of HBO and mitochondrial bioenergetic function in the face of CO poisoning.

In a previous study, we explored the logistics of measuring mitochondrial respiration that fits in an analytical timeframe useful to identify clinical abnormalities and we also found that clinically significant CO poisoning resulted in a decrease in key parameters of mitochondrial respiration regardless of the carboxyhemoglobin (COHb) level [8]. In this study, we used freshly obtained blood cells to perform simultaneous measurement of mitochondrial respiration and reactive oxygen species (ROS) production (e.g., hydrogen peroxide or H$_2$O$_2$ production). We evaluated blood samples from control subjects as well as subjects with clinically significant CO poisoning upon hospital presentation and also immediately after an initial treatment of HBO. The primary objective of this study was to assess changes in mitochondrial function that occur as a result of CO poisoning and subsequent HBO therapy.
Methods

Study design

The University of Pennsylvania Institutional Review Board approved this study and informed consent was obtained from all subjects. This was a two-group controlled experiment of acutely CO-poisoned subjects undergoing HBO treatment and control subjects. Whole blood was obtained from consented participants 1 h after emergency department (ED) presentation and immediately after undergoing HBO treatment. The first HBO treatment was at 2.8 ATA or atmospheres absolute pressure (60 ft of seawater pressure or 2.8 times of atmospheric pressure) for 120 min as seen in Fig. 1. We also obtained the following clinical information: history, physical exam, standard laboratory values, imaging studies, COHb, and hospital outcomes. Exclusion criteria for both groups include known malignancy, pregnancy, and oncology history with active chemotherapy by chart review and/or clinical assessment.

Human blood cell preparation

All eligible subjects with confirmed CO poisoning underwent phlebotomy as part of standard care within 1 h of ED presentation and within 1 h after the initial HBO treatment. Samples were taken from the collection tubing at the same time as a planned blood phlebotomy. A volume of 15 ml was drawn in K₂EDTA tubes to prohibit platelet activation. The following protocol was carried out to obtain a population of peripheral blood mononuclear cells (PBMCs): 15 ml of Ficoll-Paque™ PLUS was placed into a 50-ml Leucosep tube (Greiner Bio-one) which was centrifuged at 1000 g for 1 min. During this process, 15 ml of the patient’s blood was added to a 50-ml Falcon tube followed by an addition of 15 ml of DPBS for a total of 30 ml in a 1:1 mixture. The 50-ml Falcon tube was gently inverted. Once the Leucosep centrifugation was completed, the 30 ml of blood was carefully pipetted and layered above the disc within the Leucosep tube. The Leucosep tube was centrifuged at 1000 g for 10 min at room

![Fig. 1](image-url) Treatment Table 5 for CO poisoning. The standard HBO protocol for patients with CO poisoning. All subjects in the CO group underwent HBO treatment at 2.8 ATA (60 ft of seawater pressure or 2.8 times of atmospheric pressure) for 120 min.
temperature after which approximately 4 ml of the buffy coat containing PBMCs was collected. This buffy coat sample was placed in a 15-ml tube followed by the addition of 4 ml of DPBS for a 1:1 mixture that was then centrifuged at 1000 g for 7 min. The supernatant was discarded and the PBMC pellet was gently re-suspended in MiR05 medium for high-resolution respirometry. A cell count with trypan blue was performed with the Cell Countess II (Invitrogen) and cell viability was also assessed. To demonstrate that our sample preparation methodology yields PBMCs to a high degree, we performed flow cytometry analysis. Our use of the Leucosep tube resulted in samples having over 95% PBMCs and less than 5% erythrocytes and platelets combined.

High-resolution respirometry
Respiration was measured at a constant temperature of 37 °C in a high-resolution oxygraph (Oxygraph-2k, OROBOROS Instruments) in 2-ml glass chambers with stirrer speed 750 rpm. Data were recorded with DatLab software 6 (OROBOROS Instruments) with the sampling rate set to 2 s. All experiments were performed at an oxygen concentration in the range of 210–50 μM O₂ corrected for background flux. For respiration measurements in permeabilized cells, PBMCs were suspended in a mitochondrial respiration medium (MiR05) containing sucrose 110 mM, HEPES 20 mM, taurine 20 mM, K-lactobionate 60 mM, MgCl₂ 3 mM, KH₂PO₄ 10 mM, EGTA 0.5 mM, and BSA 1 g/l and with pH 7.1 which allows for the simultaneous measurement of respiration and H₂O₂ production.

Experimental protocol for reference protocol for permeabilized cells
We performed a specialized protocol using PBMCs to evaluate specific complex (CI-CIV) activity that requires controlled permeabilization with digitonin. This substrate-uncoupler-inhibitor titration (SUIT) protocol is referred to as reference protocol (RP) designed to provide common reference for comparison of respiratory control in a wide range of preparations ranging from isolated mitochondria, tissues, and various cell types including human blood cells utilized in this experiment [8, 11]. In order to access the electron transport system with saturating exogenous substrates and inhibitors, the plasma membrane was permeabilized with the detergent digitonin. A set of experiments were performed to establish the optimal concentration of digitonin to induce maximal permeabilization of the plasma membrane without affecting the outer or inner mitochondrial membrane. Figure 2 illustrates a typical respiration tracing utilized for our study with the following sequence of injections given in the RP to establish the respiratory capacities with electron flow through both CI and CII separately as well as convergent electron input via the Q-junction (CI + II). Both malate and pyruvate (PM) were added prior to the addition of cells. Once cells were added, routine respiration was allowed to be reached followed by titration with digitonin for permeabilization of the plasma membrane in the concentration described above which provides CI-linked LEAK state. Oxidative phosphorylation (OXPHOS) capacity of CI, driven by nicotinamide adenine dinucleotide (NADH)-related substrates, was evaluated by adding adenosine diphosphate-(D). Carbonyl cyanide m-chlorophenyl hydrazine (U) was titrated to obtain the maximal respiratory capacity or ETS. ETS is the maximum stimulation of mitochondrial respiration that is measured after the use of a protonophore that uncouples oxidative phosphorylation. ETS is often thought
of as the maximal reserve for the cell to perform biochemical work. After U titration, glutamate (G) was added to obtain uncoupled CI respiration (ETS$_{CI}$) that was added followed by succinate (S) to give uncoupled CI and CII respiration (ETS$_{CI+ CII}$). CI was inhibited by rotenone (Rot) to assess the ETS capacity supported by succinate through CII only or uncoupled CII respiration (ETS$_{CII}$). After, glycerol 3-phosphate (Gp) was given to evaluate mitochondrial glycerophosphate dehydrogenase complex that feeds electrons directly to ubiquinone. Finally, electron flow through the ETS was inhibited by addition of antimycin-A (Ama), inhibiting CIII, providing the residual oxygen consumption (ROX) not related to non-mitochondrial oxygen consumption. ROX was subtracted from the different respiratory parameters in further analyses. CIV activity was then assessed with the addition of both ascorbate and N,N,N′,N′-tetramethyl-p-phenylenediamine dihydrochloride (Tm) followed by sodium azide (Azd). For correction of non-CIV-related oxygen consumption, the remaining chemical background was subtracted.

**Experimental protocol for the simultaneous measurement of hydrogen peroxide in permeabilized cell**

In addition to the measurement of mitochondrial respiration in permeabilized cells, we also simultaneously measured the production of ROS as H$_2$O$_2$. All experiments were conducted with an O2k-Fluorometer LED2-Module connected to the O2k-Core using two fluorescence sensors green with the gain set to 1000 with a polarization of 400 mV (400 mV was an ideal balance between sensitivity and photobleaching). The following injections were performed prior to the injection of cells: (1) Amplex Red (AmR) was added followed by the addition of horseradish peroxidase that is necessary for the conversion of H$_2$O$_2$ and AmR to resorufin (fluorescence). Next superoxide dismutase was added to convert any superoxide to H$_2$O$_2$. The final injection prior to the addition of cells was freshly prepared H$_2$O$_2$ to test the AmR assay system and to allow calibration of the O2k-Fluorometer for AmR. Additionally, we have performed experiments with the use of resorufin as an internal control in a dose-dependent fashion to test for H$_2$O$_2$ signal and our prior work describes this technique [12, 13].
**Data analysis**

Statistics were calculated by using Graph Pad Prism v.7 (GraphPad Software Inc.). Data were tested for normal distribution with the D'Agostino and Pearson omnibus normality test. Data are presented as mean ± SEM if not indicated otherwise. Differences between the control group and the CO group (before and after HBO therapy) were analyzed with repeated measures ANOVA and, when significant, paired Student's t tests were performed between the respiratory states. The results were adjusted with Bonferroni correction for multiple tests. A P value of < 0.05 was considered statistically significant.

**Results**

We enrolled a total of 17 subjects, including seven subjects with confirmed CO poisoning (CO group) and 10 healthy subjects (control group). The patient characteristics are presented in Table 1. The subjects in the control group were enrolled as a healthy convenience sample to serve as a comparison group for the measurement of mitochondrial respiration and ROS. The subjects in the control group were 50% male with a median age of 40 years (IQR, 36 to 51 years). Subject clinical characteristics included the following: six (60%) had no medical problems, one had obstructive lung disease, and three had hypertension. All subjects were discharged from the emergency department with no return visit on a 30-day chart review. The subjects in the CO group included five men (71%) and two women (29%). The median age of CO subjects enrolled was 67 (IQR, 47 to 68 years). Patient clinical characteristics included the following: four (57.1%) had no medical problems, one had Parkinson's disease, and two had hypertension. Regarding the source of CO exposure, four (57.1%) were related to a faulty heat generator, two (28.6%) were related to occupational exposure involving machinery, and one (14.3%) was related to a car exhaust.

| Table 1 | Characteristics of subjects in the CO and control group |
|---------|----------------------------------------------------------|
| Characteristics | Carbon monoxide group (n = 7) | Control group (n = 10) |
| Age | 67 (47–68) | 40 (36–51) |
| Sex (%) | | |
| Male | 71 | 50 |
| Female | 29 | 50 |
| Laboratory value | | |
| COHb (%) | 29 (28–32) | |
| Lactate (mmol/L) | 2.78 (1.1–4.5) | |
| Clinical symptoms (%) | | |
| Neurological | | |
| Headache | 57 | |
| Seizure | 14 | |
| Syncope | 43 | |
| Cardiac | | |
| Chest pain | 14 | |
| EKG changes | 14 | |
| Gastrointestinal | | |
| Nausea and emesis | 14 | |

Data presented as median (IQR) or as percentage
In the CO group, on arrival at the ED, four (57.1%) experienced syncope, one (14.3%) had a seizure, two (28.6%) presented with chest pain/EKG changes, and one (14.3%) presented with nausea and vomiting. Following arrival at the ED, six (85.7%) subjects were placed on non-rebreather mask and one (14.2%) was intubated for altered mental status. As an outcome index, one subject was admitted to the ICU, one was admitted to a general medicine floor for residual weakness, and five were discharged from the observation unit after undergoing three HBO dives. All seven CO subjects survived hospitalization.

We compared mitochondrial function in PBMCs obtained from subjects in the CO group at two discrete time points, prior to HBO therapy and within 1 h after undergoing the initial HBO treatment as seen in Fig. 3. We also compared respiration results in the CO group (pre- and post-HBO) to the control group. All the units of respiration were measured in pmol $O_2 \times s^{-1} \times 10^{-6}$ PBMCs. Table 2 contains both mitochondrial respiration and $H_2O_2$ production at all the key respiratory states.

The following key parameters of respiration was significantly lower in the CO group (pre-HBO) when compared to the control group, respectively: OXPHOS $CI$, ETS or maximal respiration, ETS $CI$, ETS $CI+CII$, and CIV respiration. There were no differences in $R$, LEAK, ETS $CI$, $G_p$, and ROX between the two groups. There was a significant overall increase in respiration in the CO group after they underwent HBO when compared to pre-HBO treatment except with no differences in respiration with $R$, LEAK, $G_p$, and ROX. Also of note, the control group and the CO group (post HBO) were similar in all respiratory states.

We also determined the rate of $H_2O_2$ production (as well as superoxide converted to $H_2O_2$ with the administration of SOD) simultaneously with the measurement of respiration in Fig. 4. The final $H_2O_2$ production values were obtained after correction for both background fluorescence and changes in sensitivity over time. There were no differences in $H_2O_2$ production between the CO group (pre-HBO) versus the control group. There
Table 2 Mitochondrial respiration and H$_2$O$_2$ production

| Respiratory states | Control group Mean | SEM | CO group (pre-HBO) Mean | SEM | CO group (post-HBO) Mean | SEM |
|--------------------|--------------------|-----|-------------------------|-----|-------------------------|-----|
| Mitochondrial respiration (measured in pmol O$_2 \times s^{-1} \times 10^{-6}$ PBMCs) | | | | | | |
| Routine            | 19.56              | 0.54 | 13.23                   | 1.42 | 22.10                   | 1.28 |
| LEAK               | 13.33              | 0.97 | 6.19                    | 0.99 | 13.54                   | 1.81 |
| OXPHOS             | 20.57              | 0.87 | 8.47                    | 1.45 | 17.51                   | 2.58 |
| ETS                | 35.66              | 2.20 | 18.39                   | 2.42 | 35.23                   | 3.70 |
| ETS-CI             | 41.73              | 2.76 | 19.81                   | 1.77 | 38.07                   | 3.61 |
| ETS-CI&II          | 58.04              | 2.33 | 32.27                   | 3.17 | 60.54                   | 3.32 |
| ETS-CII            | 20.67              | 2.11 | 16.44                   | 1.30 | 28.07                   | 2.25 |
| Gp                 | 55.86              | 5.96 | 47.86                   | 6.36 | 47.15                   | 3.88 |
| ROX                | 1.17               | 0.20 | 0.73                    | 0.19 | 0.76                    | 0.20 |
| CIV                | 63.60              | 6.03 | 43.52                   | 2.92 | 76.50                   | 4.30 |
| Mitochondrial H$_2$O$_2$ production (measured in pmol H$_2$O$_2 \times s^{-1} \times 10^{-6}$ PBMCs) | | | | | | |
| Routine            | 0.06               | 0.02 | 0.04                    | 0.02 | 0.16                    | 0.07 |
| LEAK               | 0.18               | 0.05 | 0.24                    | 0.13 | 0.92                    | 0.14 |
| OXPHOS             | 0.25               | 0.05 | 0.16                    | 0.05 | 0.93                    | 0.22 |
| ETS                | 0.22               | 0.04 | 0.14                    | 0.02 | 0.85                    | 0.20 |
| ETS-CI             | 0.22               | 0.04 | 0.13                    | 0.02 | 0.66                    | 0.21 |
| ETS-CI&II          | 0.22               | 0.04 | 0.17                    | 0.02 | 1.14                    | 0.32 |
| ETS-CII            | 0.26               | 0.06 | 0.23                    | 0.04 | 0.71                    | 0.08 |
| ROX                | 0.57               | 0.15 | 0.31                    | 0.06 | 1.59                    | 0.42 |

Cellular mitochondrial respiration and hydrogen peroxide production obtained in permeabilized PBMCs between the control group, CO (pre-HBO) group, and the same CO group after undergoing HBO treatment (post-HBO). Values presented as mean ± SEM.

Fig. 4 ROS production in PBMCs. Measurement of ROS production using the Amplex Red assay. H$_2$O$_2$ levels are measured in the presence of superoxide dismutase to ensure that all superoxide is converted into H$_2$O$_2$. Values presented as mean ± SEM. *The CO group (pre-HBO) is significantly different after their HBO treatment (post-HBO) and from the control group (P < 0.001 for both groups).
was a significant increase in all key parameters of $H_2O_2$ production measured in pmol $H_2O_2 \times s^{-1} \times 10^{-6}$ PBMCs in the CO group after they underwent HBO treatment when compared to pre-HBO treatment with the exception of routine indicating an effect of HBO therapy on $H_2O_2$ production. $H_2O_2$ production was also significantly higher in the same CO group after HBO treatment when compared to the control group with the exception of R.

Discussion

The present study investigates the changes in both mitochondrial respiration and hydrogen peroxide production in PBMCs obtained from subjects who were poisoned by CO undergoing their first treatment of HBO (2.8 ATA for 120 min). The findings of this study were that PBMCs obtained from subjects with CO poisoning when compared to the control group exhibited an overall decrease in mitochondrial respiration. Importantly, for the CO subjects who underwent the first treatment of HBO, there was an overall increase in mitochondrial respiration post HBO with the exception of glycerophosphate dehydrogenase complex (CGpDH) activity which is a complex of the electron transfer system localized at the outer face of the inner mt-membrane. In regard to $H_2O_2$ production, there was an overall increase in $H_2O_2$ production along the main parameters of mitochondrial respiration post HBO treatment for the CO group.

One of the findings in this study was a decrease in CIV respiration in the CO group when compared to the control group. We previously showed a decrease in CIV respiration in PBMCs obtained from a subset of subjects with severe CO poisoning related to death. In addition to the effect of CO on CIV activity, we also found that the measurement of mitochondrial respiration served as a better clinical indicator of outcome when compared to a COHb level [8]. Earlier studies have also demonstrated CIV inhibition where one study showed sustained inhibition [14–16]. However, there are a number of methodological issues with these early studies to consider. The one study that demonstrated sustained CIV inhibition only contained three subjects who were also actively smoking during the repeat measures of CIV activity [14]. It is known that cigarettes contain both CO and a small amount of cyanide, which is a significant cofounding factor. Another limitation of another study include the use of an in vitro model using striated muscle artificially exposed to CO and frozen samples with delayed results unlikely to affect clinical care utilizing the use of spectrophotometry [15, 16]. In general, spectrophotometry requires homogenization of samples with a high risk of mitochondrial damage and more artificial conditions when compared to HRR.

One of the strengths of performing HRR in permeabilized cells is that it allows examination of a variety of respiratory states at each complex. In this current study, there was a decrease in CIV respiration most likely secondary to inhibition from CO. This RP SUIT provides various coupling states, and in particular, CIV respiration can be obtained after the inhibition of CIII with Ama. CIV is provided with specific compounds as described in our method to obtain specific CIV respiration. This specific sequence of injections ensures that the CIV respiration obtained is not from the contribution of other complexes. In another study we performed, intact PBMCs obtained from healthy subjects exposed to cyanide (CIV inhibitor) resulted in an overall decrease in mitochondrial respiration in all the main parameters of respiration measured in intact cells that include R and ETS [17]. In our present study, the overall improvement
in respiration in subjects who were treated with HBO therapy may have been due to the enhanced removal of CO at CIV restoring electron flow upstream. While based on the current literature, inhibition of CIV resulting from CO binding effect will slow down respiration at other complex that is the likely explanation for our findings. Also another important consideration is that our CO group had variable clinical severity of CO poisoning which can also account for this finding. A third consideration is that CO also causes hypoxia where CI is sensitive to hypoxia so the decrease in CI activity is more likely from CI injury as opposed to direct CI inhibition [18, 19].

We utilized an innovative technique of simultaneously measuring both cellular respiration and H$_2$O$_2$ production with the AmR system. This method has been applied in a limited number of studies but provides important information regarding H$_2$O$_2$ production in relation to cellular respiration [13, 20]. The measurement of ROS in real time can be technically challenging as it depends on a number of factors such as the type of ROS, timing, and technique. For example, the measurement of superoxide is technically more challenging, as this species is short-lived and immediately converted to H$_2$O$_2$ through SOD [21]. The measurement of H$_2$O$_2$ production confers certain advantage as H$_2$O$_2$ is a more stable compound and its measurement is well established. In our study, we did use SOD that converts all superoxide radicals to H$_2$O$_2$ so the H$_2$O$_2$ production we obtained reflects both superoxide and H$_2$O$_2$ production.

In addition to measuring mitochondrial respiration, we also simultaneously measured H$_2$O$_2$ production in PBMCs obtained from subjects poisoned with CO compared to the control group. We found that there was no difference in H$_2$O$_2$ production between the CO (pre-HBO) group and the control group. This is consistent as CI and CIII are considered the major sites for ROS production whereas CIV is generally not a source of ROS production as seen with our results. However, there is some evidence that CIV inhibition can lead to increased reduction of redox centers in CI or CII with potential ROS generation [22, 23]. The results in our study do support that CIV inhibition with CO alone does not result in significant ROS production. It is important to note that the use of strongly redox active substances such as cytochrome c are incompatible with the AmR assay so once CIV substrates were given to obtain CIV respiration only H$_2$O$_2$ production up until the injection of Ama is a reliable reflection of H$_2$O$_2$ production.

All of the CO subjects underwent HBO therapy, and repeat measurements in PBMCs obtained from the CO group immediately following HBO showed significant increased H$_2$O$_2$ production in the majority of the parameters of respiration. HBO therapy is the established treatment modality for CO poisoning. Subjects who undergo HBO breathe 100% O$_2$ while exposed to increased atmospheric pressure. Exposure to greater than 1 atmosphere of oxygen results in an increase in the production of ROS, and this increased production of ROS is utilized clinically for other indications of HBO such as wound healing. ROS as well as reactive nitrogen species includes a variety of species such as superoxide radicals and H$_2$O$_2$ that are predominantly generated by the mitochondria in addition to other organelles such as the endoplasmic reticulum and peroxisomes [24]. ROS play a critical role in the function of the mitochondria, involved in signaling, and participate in important redox reactions [25]. Despite the multitude of biological functions ROS participate in, excessive generation of ROS has been implicated in a number of pathological disease states such as diabetes and heart disease but include acute illnesses such as sepsis and cardiac arrest [26–28].
Our results show that the initial HBO treatment in the CO group resulted in a significant increase in H$_2$O$_2$ production most likely related to HBO with increased oxygen. It should be noted that H$_2$O$_2$ production is elevated in virtually all states in the CO group after HBO treatment, long before addition of Ama so it is not the use of Ama that results in increased H$_2$O$_2$ as Ama is used in both groups. Equation 1 illustrates the time-dependent relationship between oxygen concentration and superoxide formation:

$$\frac{d[O_2]}{dt} = k \ [O_2][R•]$$

The overall production of superoxide will vary depending on tissue type, the respiratory state of the mitochondria, and also mitochondrial inhibition. In general, CI and CIII are the primary sites of ROS generation which may be further increased with the use of certain inhibitors such as Rot for CI and Ama for CIII although results have varied depending on the tissue or cell type [22].

In our study, when comparing CIII (Ama) with CI (Rot) inhibition, there was no significant difference ($P = 0.06$). Another factor to consider for the elevated H$_2$O$_2$ in our study is the use of immune cells to measure H$_2$O$_2$. Certain immune cells such as neutrophils mediate elimination of foreign organisms such as bacteria and fungi with superoxide that is produced by NADPH oxidases located on the cell membrane [29]. Another source of ROS may be from immune cell activation. However, it has been shown that HBO results in decreased immune response from specific cell types such as monocytes which is part of the reason HBO is used for wound healing [30]. The implications of increased H$_2$O$_2$ production in the setting of CO poisoning and treatment is an important question as it is not clear if this is pathological or due to increased cellular messaging. Our study does not address the fate of the H$_2$O$_2$ produced as it may go on to become H$_2$O or a hydroxyl radical, the latter being a very potent oxidant. This would warrant further study with HBO as this may help to explain the mixed results of the effectiveness of HBO in the treatment of CO poisoning.

The primary objective of this study was to examine measurement of both respiration and H$_2$O$_2$ production, as these may have important roles in prognosis and treatment as a clinical bedside tool. In our study, we were able to obtain both respiration and H$_2$O$_2$ production in the CO groups prior to the subjects undergoing their initial HBO treatment. Specifically, we are able to obtain results from the time of blood sample drawn to data in under 2 h [31]. It is not uncommon that the time required for patients to undergo initial evaluation for CO poisoning in the ED and then be transported to facilities for HBO treatment is greater than this. Our work describes the measurement of both mitochondrial respiration and H$_2$O$_2$ production in CO poisoning. It has potential application as a bedside tool in the acute care and treatment of patients having other forms of metabolic dysfunction resulting from poisoning or sepsis [31].

**Limitations**

There are some limitations to consider with the present study. An important limitation is the lack of inclusion of a control group of healthy subjects who undergo HBO without having any clinical need for such therapy. HBO therapy, while having a favorable safety profile, is not without complications. The risk of barotrauma increases
even at 1.2 ATA and subjects may experience otalgia and barotrauma to other areas such as the sinuses. Another complication is oxygen-induced seizure with a risk of up to 1/100 at 2.8 ATA [32]. In consideration of these complications, we chose not to incorporate volunteer subjects exposed to HBO therapy. Future studies could perform testing on patients not poisoned with CO who receive hyperbaric therapy for a non-acute illness such as wound healing although the depth of the dive may differ. Another limitation is the lack of CO-exposed subjects who did not undergo HBO therapy. It is not clear how both mitochondrial respiration and H$_2$O$_2$ production would have changed without HBO treatment. For ethical reasons, HBO therapy was not withheld from any CO subject who met indications for HBO treatment. However, we note that repeat measures of mitochondrial function could be performed on patients who did not undergo HBO, as many patients with CO poisoning do not receive HBO [33]. A third limitation of this study is the connection between the use of human blood cells as a marker of mitochondrial function in vital organs such as the brain and heart that are affected in CO poisoning. An animal model of hemorrhagic shock has been used to evaluate blood cells as a marker of organ mitochondrial function [34]. The advantage of using blood cells as a surrogate biomarker to assess organ mitochondrial function is very attractive for both clinical and research reasons. Blood cells are easily accessible with minimal risk via venipuncture, and samples can be obtained repeatedly to assess mitochondrial function over time and in response to treatment. Finally, another consideration is the novelty of simultaneous measurement of respiration and H$_2$O$_2$ production. At this time, the current ROS that can be readily tested for is H$_2$O$_2$ and superoxide to some extent. A limitation is that other ROS such as hydroxyl radical or other nitrogen-based species are not tested so it may give an incomplete picture involving ROS.

**Conclusions**

In this study, PBMCs obtained from subjects with confirmed CO poisoning have an overall decrease in respiration but similar H$_2$O$_2$ production when compared to controls. In the CO group who all underwent treatment with HBO, PBMCs obtained immediately after the first treatment of HBO displayed an overall increase in respiration and H$_2$O$_2$ production. The study findings demonstrate that treatment with HBO resulted in improved cellular respiration but higher H$_2$O$_2$ production. It is unclear if the increased production of H$_2$O$_2$ in HBO treatment is detrimental.

**Abbreviations**

Ama: Antimycin—Complex III inhibitor; AmR: Amplex red—extrinsic fluorophore for measurement of hydrogen peroxide production as resorufin; Axd: Azide—Complex IV inhibitor. To obtain CIV respiration, once Tm is given, this is followed by Axd. The difference between the two will provide CIV respiration; CI-IV: Complex I-IV; D: Adenosine diphosphate (ADP)—substrate of ANT and ATP synthase in the phosphorylation system; G: Glutamate—supporting an N-linked (Complex I) pathway control state; Gp: Glycerophosphate—substrate for electrons donation to ubiquinone; HRR: High-resolution respirometry (Measured with the OROROROS O2K); H$_2$O$_2$: Hydrogen peroxide—one of several reactive oxygen intermediates; L: LEAK respiration—dissipative component of respiration which is not available for performing biochemical work; P: OXPHOS capacity—is the respiratory capacity of mitochondria in the ADP-activated state of oxidative phosphorylation; PM: Pyruvate and malate—used to obtain LEAK state; R: ROUTINE respiration—cellular energy demand, energy turnover and the degree of coupling to phosphorylation often representing steady state; Rot: Rotenone—Complex I inhibitor; ROX: Residual oxygen consumption—respiration due to oxidative side reactions remaining after inhibition of the electron transport system (Rot and Ama); RP: Reference protocol—provides a common baseline for comparison of mitochondrial respiratory control in a large variety of species, tissues and cell types (see Fig. 2 for example of typical tracing); S: Succinate—Complex II substrate; SUIT: Substrate-uncoupler-inhibitor titration—sequence of compounds given to obtain various coupling states; Tm: Denotes the injection of N,N,N',N'-tetramethyl-p-phenylenediamine dihydrochloride, which is an artificial substrate
for reducing cytochrome c in the respirometric assay for cytochrome c oxidase (CV) activity followed by ascorbate that maintains N,N,N′,N′-tetramethyl-p-phenylenediamine dihydrochloride in a reduced state; U: Carbonyl cyanide m-chlorophenyl hydrazine—a protonophore (H+ ionophore) and is used as a potent chemical uncoupler of oxidative phosphorylation

Acknowledgements
Gerhard Krumschnabel, PhD from OROBOROS Instruments for feedback on the H2O2 data obtained and The Society for Redox Biology and Medicine (SRBM) Mini-Fellowship which provided the author (DJ) funding to spend 4 weeks at OROBOROS Instruments to learn the technique of simultaneous measurement of respiration and H2O2 production in various cell lines are acknowledged.

Funding
1. K08HL136858 from the National Heart, Lung, and Blood Institute (DJ). 2. N000141612100 from the Office of Naval Research (DME). 3. American College of Medical Toxicology (ACMT)-Medical Toxicology Foundation Research and Teaching Award (DHJ and UGK).

Authors’ contributions
DHJ is the primary author who performed majority of experiment. UGK is responsible for clinical data collection and processing and manuscript preparation. BPS is responsible for statistical support and manuscript review. MK, KH, and DSL are responsible for patient enrollment and manuscript production. DME is the senior author who provided critical guidance for the manuscript; work was in his lab. All authors read and approved the final manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Emergency Medicine, Division of Medical Toxicology and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, John Morgan Building, 3620 Hamilton Walk, Philadelphia 19104, PA, USA. 2Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia 19104, PA, USA. 4Department of Emergency Medicine, Division of Hyperbaric and Undersea Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. 5Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, USA. 6Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, USA. 7Cardiovascular Institute, University of Pennsylvania, Philadelphia, USA.

Received: 5 September 2017 Accepted: 10 January 2018
Published online: 30 January 2018

References
1. Rose JJ, Wang L, Xu Q et al (2017) Carbon monoxide poisoning: pathogenesis, management, and future directions of therapy. Am J Respir Crit Care Med 195(5):596-606
2. Ran T, Nummagambetov T, Sirac K (2017) Economic implications of unintentional carbon monoxide poisoning in the United States and the cost and benefit of CO detectors. Am J Emerg Med. https://doi.org/10.1016/j.ajem.2017.08.048
3. Pepe G, Castelli M, Nazerian P et al (2011) Delayed neuropsychological sequelae after carbon monoxide poisoning: predictive risk factors in the emergency department. A retrospective study. Scand J Trauma Resusc Emerg Med 19(16). https://doi.org/10.1186/1757-7241-19-16 PMID: 2141211
4. Thorn SR, Taber RL, Mendiguen I I et al (1995) Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med 25(4):474–480 PMID: 7710151
5. Thorn SR (1990) Carbon monoxide-mediated brain lipid peroxidation in the rat. J Appl Physiol (1985) 68(3):997–1003
6. Thom SR (1995) Leukocytes in carbon monoxide-mediated brain oxidative injury. Toxicol Appl Pharmacol 129(3):247–247
7. Chang CK, Taylor TG (1975) Kinetics of oxygen and carbon monoxide binding to synthetic analogs of the myoglobin and hemoglobin active sites. Proc Natl Acad Sci U S A 72(3):1166-1170
8. Jang DH, Kelly M, Hardy K, Lambert DS, Shofer FS, Eckmann DM (2017) A preliminary study in the alterations of mitochondrial respiration in patients with carbon monoxide poisoning measured in blood cells. Clin Toxicol (Phila) 55(6):579-594.
9. Weaver LK, Hopkins RO, Chan KJ et al (2002) Hyperbaric oxygen for acute carbon monoxide poisoning, N Engl J Med 347(4):1057–1067
10. Buckley NA, Juurlink DN, Isbister G et al (2011) Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev (4):CD002041
11. Pestal D, Gnaiger E (2012) High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol 810:25–58
12. Krumschnabel G, Fontana-Ayoub M, Sumbalova Z et al (2015) Simultaneous high-resolution measurement of mitochondrial respiration and hydrogen peroxide production. Methods Mol Biol 1264:245–261
13. Jang DH, Seeger SC, Grady ME et al (2017) Mitochondrial dynamics and respiration within cells with increased open pore cytoskeletal meshes. Biol Open 6(12):1831-1839.
14. Miró O, Casademont J, Barrientos A et al (1998) Mitochondrial cytochrome c oxidase inhibition during acute carbon monoxide poisoning. Pharmacol Toxicol 82(4):199–202
15. Alonso JR, Cardellach F, López S et al (2003) Carbon monoxide specifically inhibits cytochrome c oxidase of human mitochondrial respiratory chain. Pharmacol Toxicol 93(3):142–146
16. Garrabou G, Inoriza JM, Morén C et al (2011) Mitochondrial injury in human acute carbon monoxide poisoning: the effect of oxygen treatment. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 29(1):32–51
17. Jang DH, Shofer FS, Weiss SL et al (2016) Impairment of mitochondrial respiration following ex-vivo cyanide exposure in peripheral blood mononuclear cells. Clin Tox 51(1–5):268–26815
18. Dróse S, Stepanova A, Galion A (2016) Ischemic A/D transition of mitochondrial complex I and its role in ROS generation. Biochim Biophys Acta 1857(7):946–957
19. Gorenkova N, Robinson E, Grieve DJ et al (2013) Conformational change of mitochondrial complex I increases ROS sensitivity during ischemia. Antioxid Redox Signal 19(13):1459–1468
20. Karlsson M, Hari N, Morata S et al (2016) Diverse and tissue-specific mitochondrial respiratory response in a mouse model of sepsis. Shock 45(4):404–410
21. Turrens JF (1997) Superoxide production by the mitochondrial respiratory chain. Biosci Rep 17(1):3–8
22. Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552(Pt 2):335–344
23. Chen Q, Vazquez EJ, Moghaddas S et al (2003) Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem 278(38):36027–36031
24. Thom SR (2011) Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg 127(Suppl 1):1315–1415
25. Thom SR (2009) Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol (1985) 106(3):988–995
26. Martins PS, Kallas EG, Neto MC et al (2003) Upregulation of reactive oxygen species generation and phagocytosis, and increased apoptosis in human neutrophils during severe sepsis and septic shock. Shock 20(3):208–212
27. Sugamura K, Keaney JF Jr (2011) Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 51(5):978–992
28. Sanderson TH, Reynolds CA, Kumar R et al (2013) Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol Neurobiol 47(1):9–23
29. Forman HJ, Torres M (2002) Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. Am J RespCrit Care Med 166(12 Pt 2):S54–S58
30. Saito K, Tanaka Y, Ota T et al (1991) Suppressive effect of hyperbaric oxygenation on immune responses of normal and autoimmune mice. Clin Exp Immunol 86(2):322–327
31. Jang DH, Greenwood J, Spores MB, Eckmann DM (2017) Measurement of mitochondrial respiration and motility in acute care: sepsis, trauma and poisoning. J Intensive Care Med 32(1):86–94.
32. Smerz RW (2004) Incidence of oxygen toxicity during the treatment of dysbarism. Undersea Hyperb Med 31(2):199–202
33. Hampson NB, Little CE (2005) Hyperbaric treatment of patients with carbon monoxide poisoning in the United States. Undersea Hyperb Med 32(1):21–26
34. Karamercan MA, Weiss SL, Villarroel JP et al (2013) Can peripheral blood mononuclear cells be used as a proxy for mitochondrial dysfunction in vital organs during hemorrhagic shock and resuscitation? Shock 40(6):476–484